Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;29(7):653-5.
doi: 10.1007/s10585-012-9483-3. Epub 2012 Jun 8.

Molecular profiling for personalized cancer care

Affiliations

Molecular profiling for personalized cancer care

Raheela Ashfaq. Clin Exp Metastasis. 2012 Oct.

Abstract

The pace of genomic discoveries in the field of cancer is revolutionizing our understanding of the biological dynamics of cancerous growth and, at the same time, fueling research for newer and smarter cancer therapies to reverse the effects of these alterations. These dynamics are driving a tremendous paradigm shift in cancer diagnostics, drug development and clinical trial design with the hope of eliminating the current structure and approach of cancer care, to one which is driven by the underlying biology of the tumor and, thus highly personalized. Much of this paradigm shift has been fueled by the current availability of novel technologies, platforms and bioinformatic tools. Today, therapies are being rationally designed to target the precise genetic alterations with better clinical outcomes with reduced morbidity. Therefore, molecular profiling of tumors to identify the multiplicity of alterations in a tumor is an essential and necessary companion for targeted therapies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ross JS. Cancer biomarkers, companion diagnostics and personalized oncology. Biomarker Med. 2011;5(3):277–279. doi: 10.2217/bmm.11.29. - DOI - PubMed
    1. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol. 2010;28(35):5219–5228. doi: 10.1200/JCO.2009.27.4944. - DOI - PMC - PubMed
    1. Schilsky RL, Allen J, Benner J, Sigal E, McClellan M. Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist. 2010;15(5):484–487. doi: 10.1634/theoncologist.2010-0079. - DOI - PMC - PubMed
    1. Dhani N, Tu D, Sargent DJ, et al. Alternate endpoints for screening phase II studies. Clin Cancer Res. 2009;15:1873–1882. doi: 10.1158/1078-0432.CCR-08-2034. - DOI - PubMed
    1. Smith S, Su D, Rigault de la Longrais IA, et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in additional to platinum-based therapy. J Clin Oncol. 2007;25:5172–5179. doi: 10.1200/JCO.2007.11.8547. - DOI - PubMed

Substances

LinkOut - more resources